CompletedPhase 2

Therapy for Pediatric Hodgkin Lymphoma

United States296 participantsStarted 2000-03-02

Plain-language summary

With the success of current chemotherapy for Hodgkin's disease, the goal of this protocol is to maintain the currently successful cure rate and reduce treatment related side effects and long term toxicity. The main purpose of this study is to estimate the event free survival of patients treated with risk-adapted therapy compared to historical controls.

Who can participate

Age range21 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Non-bulky mediastinal disease (\<33% mediastinal to thoracic ratio on chest x ray)
✓. Ann Arbor stage IA or IIA with any of the following features: (1) "E" lesions (s), (2) 3 or more nodal sites involved, (3) Bulky mediastinal adenopathy (mediastinal mass to thoracic cavity ratio 33% or greater by chest radiograph)
✓. Ann Arbor stage IIB, IIIB, or any IV

What they're measuring

Event-free Survival Probability by Risk Group

Timeframe: Median 6.4 year follow-up

Trial details

NCT IDNCT00145600

SponsorSt. Jude Children's Research Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-05-31

Results submitted2013-02-12

View on ClinicalTrials.gov More Hodgkin Lymphoma trials